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We have applied two different recombinant DNA techniques to the study ofthe epidemiology
of Epstein-Barr virus infections. In the first application, cloned subfragments ofviral DNA were
used as probes todetect EBV DNA in a variety oflymphoproliferative disorders and in lymphoid
cell lines. Patients who are epidemiologically unrelated harbor EBV genotypes which can readily
be distinguished from each other. Patients who are epidemiologically related (such as mothers
and infants) have similar EBV genotypes. Some patients, especially those who are immunocom-
promised, are infected with two distinct genotypes.
In the second application, we have examined the immune response to specific EBV antigens
expressed from small cloned viral DNA subfragments. We have identified a group of patients
with presumed chronic EBV infection who selectively fail to recognize one subcomponent ofthe
EB nuclear antigen complex.
INTRODUCTION
Many epidemiologic mysteries about Epstein-Barr virus (EBV) remain unsolved.
There is the mystery of geographic pathology. The virus is associated with Burkitt
lymphoma, with endemic pockets in East Africa, and nasopharyngeal carcinoma, a
disease with high incidence in persons ofSouthern Chinese descent [1,2]. There is the
mystery of variation in clinical expression in normal individuals in our country and
other industrially developed countries. Some experience inapparent infection; others
have severe mononucleosis. There are further mysteries about pathogenesis of the
infection in abnormal hosts, such as those immunosuppressed to maintain organ grafts
or by acquired immunodeficiency syndrome, whodevelop progressive lymphoprolifera-
tive disease associated with EBV [3]. There are marked effects of age on disease
expression: the infected younger individuals more often have an inapparent infection.
There are, as so often emphasized by Alfred Evans, dramatic effects ofsocioeconomic
class and geography on virus transmission [4]. In the poor and in the Third World, the
virus seems to be acquired at an early age. All oftheseepidemiologic mysteries are, for
the present, unsolved.
MOLECULAR APPROACHES TO SOLVE THE
EPIDEMIOLOGIC QUESTIONS
Molecular biology, particularly the technology of recombinant DNA, offers the
promise of partial solution of some of these mysteries. The DNA probe technology is
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particularly suitable for comparison of the genetic make-up of different individuals,
whether they be different virus strains or different populations of hosts. Furthermore,
recombinant DNApermits thecloning andexpression ofindividual gene products. The
herpesviruses, ofwhich EBV isone, arelarge, complex organisms, which possess more
than 100 genes. Recombinant DNA permits analysis of the immune response to
individual gene products.
We hope to illustrate the application of this powerful technology to some epidemio-
logic questions concerning EBV. We shall describe experiments which concern
variations in genotype among different isolates of EBV. We shall also summarize
seroepidemiologic studies in which we measure the immune response to one individual
EBV geneproduct defined by gene transfer technology.
AN INFANT AND MOTHER INFECTED WITH TWO EBV GENOTYPES
We began by studying several EBV isolates which were obtained from a child with
AIDS who developed a central nervous system lymphoma [5]. There was a difference
between the genotype of EBV found in an isolate from a lymph node and the EBV
genotype seen in theperipheral blood and brain. We next isolated a lymphoblastoid cell
line from the patient's mother, a drug addict who was HTLVIII-seropositive, and
compared EBVsfound in the mother and the child. The mother was also infected with
two genotypes of EBV. This fact was evident by the presence of doublet restriction
fragments (Fig. 1). Furthermore, the two viruses harbored by the mother were similar
in genome structure to the two viruses found in the infant. The next question was
whether every cell in the cell line from the mother's blood contained two EBVs or
whether some cells were infected by one variant and other cells by another. A single
cell clone grown from the mother's cell line contained only one EBV. This finding
suggested that the mother's blood probably contained one population of cells with one
EBVgenotype and another with the other.
This small experiment in clinical epidemiology raised a number of interesting
questions. Is infection with multiple genotypes seen in immunologically normal hosts?
Aregenotype variants regularly found in different sites of the body? Are the multiple
genotypes the result of simultaneous infection with more than one EBV strain,
sequential infection with several EBV strains, or do they arise during virus multiplica-
tion within the infected individual?
To attempt to address some of these questions, we studied 13 more patients; seven
had uncomplicated infectious mononucleosis (IM) and six were immunocompromised
children, two immunocompromised as the result of liver transplantation and four
because of HIV infection. We studied two or more EBV isolates from each patient.
Sometimes they were separate isolates from the peripheral blood, separated by time;
more frequently they were isolates from different body sites. (These data have been
presented in preliminary form [Katz BZ, Miller G: Infection with multiple genotypes
ofEpstein-Barr virus in immunocompromised and normal hosts. Pediatr Res 20:31 3A,
1986], and amanuscript describing these experiments in detail has been submitted for
publication.) When three epidemiologically unrelated infectious mononucleosis
patients from Yale were studied, each was shown to have a distinguishable genotype of
EBV. Furthermore, multiple isolates from the same individual, for example saliva and
blood, contained similar genotypes. This finding was evidence that genotype variation
did not arise as the result ofpropagating the virus in vitro. The presence of the same
EBV genotype in saliva and lung of a child with AIDS and interstitial pneumonitis
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FIG. 1. Evidence for simultaneous infection with two
genotypes of EBV. Cell lines were established from the
lymph node and peripheral blood ofa child with AIDS and
from the peripheral blood of the child's mother. Cellular
B DNA from these cells was digested with BamHI, electro-
E phoresed, and transferred to nitrocellulose by Southern's
method. The blot was hybridized with a probe prepared
G from a plasmid carrying the EcoRI B fragment of EBV
DNA [17]. The BamHI subfragments recognized by this
probe are indicated with letters at the right. Two prototype
K EBVvariants, FF41 and Raji, are shown in lanes 1 and 2. A
negative control consisting of human placental cell DNA
R and lacking EBV genomes is found in lane 3. The patient's
two cell lines (lanes 5-7) contain different genotypes of
EBV as distinguished by variations in the size of the
BamHI E and BamHI K fragments. The cell line from the
mother's peripheral blood (lane 8) contains two genotypes;
z BamHI fragments E and K are doublets (arrows).
Reprinted from [5] with permission of the Journal of
Infectious Diseases.
demonstrated that immunocompromised patients do not invariably harbor different
genotypes in different anatomical sites.
Epidemiologically related patients, again a child with AIDS and her mother,
demonstrated the same genotype. This finding was further evidence that EBV is
probably transmitted between mother and child. When the same patients were studied
sequentially, in one instance one month apart, in another case six months apart, the
same EBV genotypes were found on both occasions.
We did encounter two mononucleosis patients who harbored two EBV genotypes in
the peripheral blood. In one patient the cell line established by co-cultivating the
patient's blood lymphocytes with umbilical cord lymphocytes contained a doublet
restriction fragment. One ofthese variants was found in isolates from the saliva ofthe
same patient. Once again a single cell clone contained one variant, although another
cell clone apparently carried both variants.
Overall, simultaneous infection with multiple EBV genotypes could be identified in
five ofseven immunocompromised patients and two ofseven infectious mononucleosis
patients. Thus both healthy and immunocompromised patients may harbor multiple
genotypes; however, the phenomenon probably occurs more often in immunocompro-
mised than in normal hosts. In general, epidemiologically unrelated patients harbor
distinct genotypes and epidemiologically related patients harbor similar genotypes.
This fact should permit some tracking oftransmission. We have preliminary evidence
for transmission between mother and child, which has often been assumed but never
documented. Usually multiple isolates from the same patient are of similar genotype
whether obtained from different sites or at different times. These findings imply that
genotype variation is not an artifact ofin vitro propagation.
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Here are some implications of this work and, it is hoped, material for further
discussion and experimentation. Do genotype variants represent viruses with different
tissue tropisms or pathogenic potential, or are the DNA variations biologically
meaningless? Do the different genotypes vary in their antigens, particularly their
surface antigens? Would an individual infected with one genotype be immune to
infection with a different genotype? If so, does this process operate via classical
humoral antibody, cellular immunity, orperhaps at the level ofthe infected targetcell?
When multiple genotypes are identified, do they arise as the result ofsimultaneous or
sequential infection?
IDENTIFICATION OF AN EBNA GENE
We have begun to undertake epidemiologic studies using a single defined gene
product ofEB virus: one ofthe nuclear antigens, EBNA. In collaboration with Wilma
Summers, our group mapped a gene for an EBNA to the BamHI K fragment of the
EBV genome. This mapping was done by putting smaller and smaller pieces of EBV
DNA into mouse cells, using the technique of herpes simplex thymidine kinase
co-transformation. We eventually ended with a pieceofEBV DNA, about 3 percent of
the length ofthe entire genome, which caused the expression ofa nuclear antigen that,
like classical EBNA, bound chromosomes which were in metaphase [6]. This gene
encoded a polypeptide with a molecular weight of about 78 kilodaltons, which was
similar in size and antigenicity to EBNA found in cells with the whole EBV genome
[7]. To be certain that the gene we had identified encoded an EBNA, we used a large
panel of human sera with known reactivity to different EBV antigens. Sera which
contained antibody to EBV capsid andearlyantigens but which lacked anti-EBNA did
not react by immunofluorescence with the mouse cells containing the BamHI K
fragment. Only sera with anti-EBNA reacted; however, we did find five of 35 sera
which were EBNA-positive, when used on Raji cells, but which did not react with the
K antigen [6]. This result was evidence that Raji cells contained more than one EBNA
gene product, and recent studies have shown that there are at least four different
EBNA gene products in EBV-transformed cells [8].
SOME PATIENTS WITH CHRONIC EBV INFECTION SPECIFICALLY
FAIL TO RECOGNIZE THE BamHI K EBNA
We went back to find out more about the five patients in our original series who
failed to detect the K component ofEBNA (which is now also called EBNA 1). Recall
that these sera did react with other EBNAs. Two of them were patients who had
recently been infected with thevirus; Dr. Niederman has subsequently discovered that,
during acute infection, antibodies to some ofthe other EBNAs appear before antibody
to K [9]. Three of the five patients had most unusual EBV serology. These three
patients were carrying a diagnosis of "chronic EBV infection." They had persistent
fever, pneumonitis, and hematologic abnormalities after mononucleosis [10]. Their
serum antibody response was unique because they had extremely high titers to EBV
replicative antigens (viral capsid and early antigens) and they reacted very strongly
with another nuclear monoclonal antigen M, also defined by gene transfer, which we
know now to be a component of the early antigen complex [11]; however, they
specifically failed to make antibody to the K antigen [12] (Fig. 2).
We next asked whether oneofthese three patients had a mutation in her virus which
prevented it from expressing the K EBNA. Dr. Schooley of Massachusetts General
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FIG. 2. Three patients with putative chronic EBV
infection whose sera lack antibody to the BamHI K
component of Epstein-Barr nuclear antigen (EBNA
1). Shown is a Western immunoblot using six human
sera-three from patients with chronic EBV infection
(numbers 1, 2, and 3) and one each from a patient
with nasopharyngeal carcinoma (NPC), infectious
mononucleosis (IM), or normal. Reactivity with the M
antigen (a component of the diffuse early antigen) or
the K antigen (EBNA 1) is shown above each serum.
Each serum was reacted on a nitrocellulose strip to
which had been transferred EBV polypeptides from a
virus producer cell line FF41 (F) or, as a negative
control, an EBV genome negative line BJAB (B). The
sera from three patients with presumed chronic active
EBV infection did not detect the prominent 78,000
dalton polypeptide (arrow) which was seen by the
patients who had anti-K. Those three patients, how-
ever, did react with many other viral-specific polypep-
tides. M in lane I denotes molecular weight markers.
Reprinted from [12] with permission of the New
EnglandJournalofMedicine.
Hospital established a lymphoid line from the patient's blood. We found (Fig. 3) that
her cells contained a normal-sized K DNA fragment, so hervirus contains the gene for
K EBNA. Furthermore, her lymphoid cells, when cultivated in vitro, expressed the K
polypeptide product, as assayed with a human serum (RM) containing anti-K. Her
own serum, however, did not recognize the K-EBNA in her cells. This finding
suggested that thedefect in this patientlay not in herability to express theantigen, but
in her capacity to recognize it.
RESPONSE TO K DURING UNCOMPLICATED
INFECTIOUS MONONUCLEOSIS
In order to interpret the significance of the specific lack ofanti-K, we have studied
the appearance of anti-K antibodies during uncomplicated mononucleosis (Fig. 4).
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FIG. 3. A lymphoid line from a patient with pre-
sumed chronic active EBV infection who lacks antibody
to EBNA 1 contains the BamHI K (EBNA 1) nuclear
antigen. Panels A and B show immunoblots with
molecular weight markers (M), BJAB (B), Raji (R),
FF41 (F), and a lymphoid line from the patient(P#2). In
A, the immunoblot was reacted with a human serum
containing antibody to EBNA 1 (K+), and, in B, a
replicate immunoblot was reacted with the patient's
own serum (K-). Note that the K+ serum recognizes
EBNA 1 in the EBV-positive Raji and FF41 cells, and
in the patient's cell line. The patient's serum does not
react with EBNA 1, although it does recognize many
EBV replicative polypeptides. Panel C is a South-
ern blotin which lanes 1-3show 100 pg, 10 pg, and 1 pg
of a recombinant plasmid (pBR322) containing the K
DNA fragment. Lanes 4-5 show 500 ng and 50 ng of
cell DNA containing 4 and 0.4 EBV copies per cell,
respectively; lanes 6-7have 500 ngand 50 ngofcellular
DNA from the lymphoid line established from patient
2. All DNAs were digested with BamHI before electro-
phoresis, blotting, and hybridization with the cloned
BamHI Kfragment probe. Thepatient's cells contained
many copies of the K DNA fragment. Reprinted from
[12] with permission of the New England Journal of
Medicine.
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FIG. 4. Development of
BamHI K nuclear antigen
antibody in relation to
EBNA antibody presence in
43 infectious mononucleosis
cases. Numbers in paren-
theses are number of pa-
tients tested; hatched areas,
percentage of patients nega-
tive for BamHI K; stippled
areas, percentage positive
for BamHI K. Reprinted
from [9] with permission of
the Journal of Infectious
Diseases.
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TABLE 1
Serologic Response to the BamHI K Component of EBNA in Different EBV
Seropositive* Patient Populations
Anti-K Antibody Status
Patient Category No. Tested Positive Negative (%)
Healthy convalescent mononucleosis 15 15 0 (0)
Nasopharyngeal carcinoma 30 30 0 (0)
Other cancer 18 18 0 (0)
Healthy adults 33 33 0 (0)
Neuropsychiatric disease 44 44 0 (0)
Burkitt lymphoma 43 39 4a (9.3)
"Chronic mononucleosis"-Fatigue syndrome 39 35 4 (10)
"Chronic mononucleosis"-Severe syndrome 25 17 8 (32)
Children with AIDS 15 3 12 (80)
Total 262 234 28 (11)
*All have antibody toviral capsid antigen.
'Two African and two European B.L.; the latter were not EBV-associated.
Early after onset, sera tended to react with EBNA, but not with K. This suggests that
EBNA antigens, other than K, are preferentially recognized early after infection;
however, by seven months after onset of clinical IM, all the patients we studied had
developed anti-K [9].
LACK OF ANTI-K IN CHRONIC EBV INFECTION
We have recently embarked on a seroepidemiologic study, on a larger scale, of the
usefulness of the selective lack of anti-K as a diagnostic marker in chronic EBV
infection. Patients who carry the diagnosis of chronic EBV infection fall into two
categories-the common and the severe. Thecommon formconsistsofchronic fatigue,
fever, sore throat, and other constitutional symptoms which persist for more than one
year following infectious mononucleosis. In the severe form, there are more objective
clincial findings, which include thrombocytopenia, neutropenia, abnormalities in the
serum immunoglobulins, and chronic pneumonitis. Altogether, we have studied 64
patients with this diagnosis whose serum was sent to us. Thirty-nine had the common
and 25 the severe form of the syndrome. We have identified 12 patients who lack
anti-K. Eight of 25, or about one-third of those with the severe form of the clinical
syndrome, lack anti-K. Four out of 39, or about 10 percent with the common form of
the syndrome, are K-negative. We do not see lack of anti-K in most other patient
groups, including EBV seropositive normals, and patients withvarious EBV-associated
cancers (Table 1). We have noted, however, that children with AIDS and EBV-
associated lymphoproliferative disease only rarely mount an antibody response to K
[3].
Clinical andEpidemiologic Features ofthe Twelve Patients Who Lack Anti-K
The 12 patients (refer to Table 2) varied in age between ten days and 32 years at
onset of symptoms. Five developed symptoms when they were children. Two children
developed disease in the perinatal period, one ofthem possibly as the result ofin utero
infection. Thepatients were born invarious partsoftheworld, including India, France,
Nova Scotia, and Holland. Noneofthe patients were blood relatives. All patients were
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TABLE 2
Patients with Chronic Active EBV Infection Who Lack Antibody to the BamHI K
Component of EBNA
Patient
No.' Ageb Sex IMC Major Clinical Manifestations
1 18 F + Fever, anemia, pneumonitis
2 17 F _ Fever, leukopenia, vision loss, pneumonitis (died)
3 8 F - Hyper IgG, thrombocytopenia
4 27 M + Hyper IgE, neutropenia, Job's syndrome
5 5 M + Hyper IgG, ascites, pneumonitis
6 2 months F - Fever, leukopenia, thrombocytopenia
7 5 F + Sinusitis, cartilage destruction, vision loss
8 10 days F - Fever, anemia, leukopenia, hepatosplenomegaly
9 31 M + Lymphadenopathy, fatigue
10 32 M + Recurrent fever, sore throat, fatigue, myalgia
11 20 F - Fever, incapacitating malaise
12 15 M + Fever, pharyngitis, myalgia
'Placeofbirth: number 2, India; number 3, France; number 5, NovaScotia; number 8, Holland; allothers,
United States
bAt onset ofsymptoms; in years, unless indicated differently
CIM, past history ofinfectious mononucleosis
HIV-seronegative, and none had an identifiable congenital immune deficiency. Thus
the syndrome of chronic EBV infection occurs in epidemiologically unrelated
patients.
Response to EBVReplicative Antigens
Another potential serologic marker for chronic EBV infection is persistent elevation
ofantibody tothecapsid and earlyantigens ofthevirus ll3,14]. All eight patients with
the clinically severe syndrome who lacked anti-K had high titers to capsid and early
antigens. Their response included high titer antibodies to monoclonal early antigens
encoded by BamHI M, HindIll G, and BamHI Z. Only one ofthe four patients with
the common form of the syndrome who lacked anti-K recognized early antigen, and
none reacted with the monoclonal early antigens M, G, and Z. This finding raises the
possibility that a panel of antigens will be needed in order to develop diagnostic
serologic techniques for the chronic EBV syndrome. In the fatigue syndrome, in
particular, it may turn out that EBV is not etiologically related.
Response to Other EBNAs
It has sometimes been argued that failureto makeantibody to EBNA is the result of
a defect in cellular immunity which prevents lysis of EBV-immortalized cells [12].
Since cells containing EBNA are healthy, they can grow in vivo, unlike cells making
early nuclear antigens, which are lysed by virus-induced cytopathic effects. Virus
products in cells which are lysed by virus replication would be readily released for
immune recognition. Immune recognition of EBNA would, however, require intact
cell-mediated cytotoxicity to break open the cell and display the nuclear antigens.
Therefore it was of considerable interest to know whether these 12 patients made
antibody to other EBNAs. Only four of 12 patients whose sera lacked antibody to K
failed to recognize EBNA in Raji cells. The remaining eight patients detected EBNA
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in Raji cells and were shown to make antibody to EBNA 2, which was expressed by
gene transfer techniques. This finding was confirmed by Western blotting experi-
ments, which demonstrated recognition ofthe EBNA 2 antigen, but not the EBNA 1
antigen, by eight patients. This evidence increases the specificity ofthe finding oflack
of antibody to EBNA 1. This lack is evidently not the result of failure to lyse
EBV-immortalized cells or to release the virus-encoded nuclear antigens to the
immune system, since antibody is made to EBNA 2. There is evidently some very
specific problem in the recognition ofthe EBNA 1 product.
GENOTYPE VARIATION IN THREE CELL LINES FROM CHRONIC
EBV PATIENTS
Thus far we have been able to study viral DNA in lymphoblastoid cell lines which
were grown from five ofthe patients. In confirmation ofour earlier results, all five cell
lines contain a BamHI K EBV DNA fragment without grossly evident deletion.
Furthermore, various probes indicate that each of these patients was infected with a
distinct genotype of EBV. This would be expected because they are epidemiologically
unrelated.
CONCLUSIONS AND IMPLICATIONS FROM USING THE BamHI K
EBNA IN SEROEPIDEMIOLOGIC STUDIES
We have found that the antibody response to BamHI K EBNA develops slowly.
Nonetheless, all EBV-seropositive individuals who are healthy have developed anti-K
by seven months after infection. Furthermore, patients with Burkitt lymphoma,
nasopharyngeal carcinoma, or caqcers not associated with EBV, have made an anti-K
response (Table 1). Some patients with symptoms and serologic evidence suggestive of
chronic active EBV infection specifically lack anti-K (Table 2). These patients do
make antibodies to other latent products (e.g., EBNA 2) and early antigens which are
found in the nucleus.
At the very least, these findings provide a serologic marker for some patients with
chronic EBV infection. Among the 25 patients with severe disease, in addition to the
eight patients whohad nodemonstrable antibody to K, werefiveothers whoseantibody
titers to K were only 1:10, though their antibody to viral capsid antigen was 1:1,000 or
higher. This finding suggests that "relative" lackofanti-K antibody may also be useful
in the serologic definition ofchronic EBV infection.
We do not know what, if any, bearing the lack of antibody to K has on the
pathogenesis of EBV infection. It is possible that an appropriate response to K is
required for successful control ofthe infection. Alternatively, lack ofanti-K may be a
marker for another, more fundamental defect.
Nor do we yet understand how the specific lack ofanti-K comes about. The studies
done so far indicate that the K product can be made by cultured cells from four
patients, but we do not have evidence that K is expressed in vivo. For five patients we
now know that a K DNA fragment is present, but finer analysis, including DNA
sequence, will be needed before we can say that this gene is entirely normal.
More likely the defect lies in one oftwo other areas. The patients may be unable to
mount an immune response to K, even though they are not globally immunodeficient.
They may be selectively immunodeficient. It is known, however, that EBNA 1 has two
antigenically distinct unrelated epitopes [15,16]. Thus failure to make anti-K must
represent an inability to recognize both epitopes.
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Perhaps the most likely explanation lies in the area of virus/cell interactions. The
lack of antibody to K may result from extensive viral replication. In the presence of
replicating virus, the K antigen may not be made or may not be positioned properly in
thecell. Alternatively, thepatients may beunable topresent theantigen totheimmune
system in the proper context. Perhaps recognition of K requires it to be in association
with cellular histocompatibility antigens or viral products. The patients may be unable
to generate this association.
Exploring molecular epidemiology quickly leads toquestionsofmolecular pathogen-
esis. This result comes as no surprise, however-as Alfred Evans and his mentor John
Paul have taught, epidemiology and pathogenesis are always intimately related.
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